This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Szadkowski, M. Articles by Jiricny, J. Search for Related Content PubMed PubMed Citation Articles by Szadkowski, M. Articles by Jiricny, J.

Characterization of the Mismatch Repair Defect in the Human Lymphoblastoid MT1 Cells

¹ Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland and ² Research Group Human Genetics, Division of Medical Genetics, UKBB DKBW, University of Basel, Basel, Switzerland

Requests for reprints: Josef Jiricny, Institute of Molecular Cancer Research, University of Zurich, August Forel Strasse 7, 8008 Zurich, Switzerland. Phone: 41-1-634-8910; Fax: 41-1-634-8904; E-mail: jiricny{at}imr.unizh.ch.

Mutations in mismatch repair (MMR) genes predispose to hereditary nonpolyposis colon cancer. Those leading to truncated proteins bring about a MMR defect, but phenotypes of missense mutations are harder to predict especially if they do not affect conserved residues. Several systems capable of predicting the phenotypes of MMR missense mutations were described. We deployed one of these to study the MMR defect in MT1 cells, which carry mutations in both alleles of the hMSH6 gene. In one, an AT transversion brings about an Asp(1213)Val amino acid change in the highly conserved ATP binding site, whereas the other carries a GA transition, which brings about a Val(1260)Ile change at a nonconserved site. The hMSH2/hMSH6 (hMutS) heterodimers carrying these mutations were expressed in the baculovirus system and tested in in vitro MMR assays. As anticipated, the Asp(1213)Val mutation inactivated MMR by disabling the variant hMutS from translocating along the DNA. In contrast, the recombinant Val(1260)Ile variant displayed wild-type activity. Interestingly, partial proteolytic analysis showed that this heterodimer was absent from MT1 extracts, although both hMSH6 alleles in MT1 cells could be shown to be transcribed with an efficiency similar to each other and to that seen in control cells. The MMR defect in MT1 cells is thus the compound result of one mutation that inactivates the ATPase function of hMutS and a second mutation that apparently destabilizes the Val(1260)Ile hMSH6 protein in human cells in vivo.

This article has been cited by other articles:

				D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045. [Abstract] [Full Text] [PDF]